Objective: Increasing evidence indicates that the decreased expression of microRNA-133a (miR-133a) may be correlated with poor survival for cancer patients. Thus, we performed this meta-analysis to evaluate the prognostic value of decreased miR-133a in solid cancers. Methods: Eligible studies were gathered by searching on PubMed, Web of Science, and Embase. Using the STATA 12.0 software, the pooled hazard ratios (HRs) and their corresponding 95% confidence intervals (CIs) for total and subgroup analyses were calculated to investigate the possible correlation between decreased miR-133a and overall survival (OS) of patients with cancer. Results: Ten studies were enrolled in this meta-analysis. The pooled result showed that decreased expression of miR-133a predicted poor OS in solid cancer patients (HR =1.62, 95% CI: 1.16-2.24, P=0.004). Compared with the total pooled HR, further analyses indicated that the subgroups of digestive system neoplasms (HR =1.73, 95% CI: 1.20-2.51, P=0.003), frozen tissue preservation (HR =1.89, 95% CI: 1.41-2.53, P,0.001), and multivariate analysis (HR =2.07, 95% CI: 1.42-3.02, P,0.001) exhibited stronger connection between decreased miR-133a expression and OS outcome.
Introduction
Cancer is one of the most important health problems of mankind. The 5-year relative survival rate for all cancers in Americans and Chinese is ~69% and 37%, respectively. 1, 2 Thus, the researches for prognostic indicators of cancer survival have important clinical values. Nowadays, numerous cancer prognostic factors have been discovered, [3] [4] [5] and the prognostic values of microRNAs also have been proved by many studies. [6] [7] [8] MicroRNAs are a kind of small noncoding RNA molecule in biology, containing ~22 nucleotides, that function in posttranscriptional regulation of gene expression and RNA silencing. 9, 10 MicroRNAs regulate tumorigenesis and cancer progression, also as gatekeepers of apoptosis for tumors. 11, 12 Through different mechanisms, microRNA can perform the role of a tumor promoter 13, 14 or cancer suppressor factor. [15] [16] [17] Meanwhile, microRNA in cancers can also be up- 18, 19 or downregulated. 20, 21 MicroRNA-133a (miR-133a) plays an important role in cancer development and progression. Studies showed that miR-133a is a tumor suppressor. 22, 23 Consequently, decreased expression of miR-133a in cancer patients correlates with poor survival and prognosis. [24] [25] [26] [27] However, the results from some studies find that lower expression of miR-133a functioned as a favorable outcome factor. 28, 29 Thus, as these submit your manuscript | www.dovepress.com
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Xiao et al results so far seem to be controversial, it is still not enough to draw a conclusion for the prognostic value of decreased miR-133a. As a fact, most researches assessing the implications of miR-133a expression in cancer were limited by the small sample sizes. Therefore, we performed this meta-analysis and expected to handle the inconsistencies of previous studies.
Materials and methods search strategy
The searches were performed by two reviewers (Jian Xiao and Yong Zou) independently. Articles were searched on PubMed, Web of Science, and Embase (updated to February 19, 2016) with language restriction of English. The search terms of keywords and their combination were as the following: "microRNA-133a OR mir-133a OR microRNA133a OR mir133a OR 133a" AND "survival OR prognosis OR prognostic" AND "cancer OR tumor OR tumour OR neoplasm OR neoplasma OR cancers OR tumors OR tumours OR neoplasms OR neoplasmas OR carcinoma OR carcinomas". A manual search for the references of relevant articles was also performed to find out other potential studies. Any differences were resolved by discussion.
inclusion and exclusion criteria
Eligible studies for this meta-analysis met the following inclusion criteria: 1) evaluated the correlation between miR133a expression and overall survival (OS) of patients with any cancer types; 2) full-text was available; and 3) reported hazard ratios (HRs) with 95% confidence intervals (CIs) or sufficient data to evaluate the HRs and 95% CIs. The exclusion criteria were the following: 1) nonhuman researches, meta-analysis, and duplicated studies; 2) letters, case reports, comments, and meeting abstracts; and 3) neither reported HR and 95% CI nor parameters (such as survival curve) to indirectly obtain them.
Data extraction
Two investigators (Jian Xiao and Xiaoxiao Lu) reviewed the eligible articles independently. Any disagreements were brought to a conclusion by discussion. Information is collected from the following items: first author; year of publication, region .50%, heterogeneity was defined, and then the randomeffects model was applied. If not, a fixed-effects model was conducted. Subgroup analysis and meta-regression were further adopted to explore the possible explanations for heterogeneity. Sensitivity analysis, by successively omitting each study, was performed to assess the stability of the results. Publication bias was evaluated by Begg's and Egger's test. P,0.05 was considered statistically significant, and all the P-values were two-tailed.
Results
eligible studies and characteristics
The initial search identified 59 potentially relevant records. After the duplicates were removed, 28 records were preserved. By further reviewing, 21 studies were determined to be of acceptable relevance and assessed for eligibility. However, eleven of them were excluded due to without OS data. Finally, ten studies met the eligible criteria and were included in this meta-analysis. [24] [25] [26] [27] [28] [29] [31] [32] [33] [34] The flow diagram on the selection process is shown in Figure 1 .
In total, 877 patients with follow-up data from four regions (People's Republic of China, Iran, Japan, and Taiwan) were included in this study. Solid cancers included in our metaanalysis derived from five cancer types: osteosarcoma, 24, 28, 33 non-small-cell lung cancer (NSCLC), 26 ,34 esophageal cancer 32 (or esophageal squamous cell carcinoma 31 ), colorectal cancer, 25, 29 and pancreatic cancer. 27 All of the miR-133a expression was tested by quantitative real-time polymerase chain reaction. The main characteristics of ten eligible studies are summarized in Tables 1 and 2 . Eligible studies for this meta-analysis (n=10)
Records were excluded for meeting abstract (n=6) Record was excluded for other topic (n=1)
Articles without overall survival data (n=11) Figure 1 Flow diagram of the selection of eligible studies. Abbreviations: ESCC, esophageal squamous cell carcinoma; NSI, no specific information; NSCLC, non-small-cell lung cancer.
Os is associated with decreased mir-133a expression
The pooled HR showed that decreased expression of miR133a was significantly associated with unfavorable OS in patients with solid cancers (HR =1.62, 95% CI: 1.16-2.24, P=0.004) (Figure 2 ). However, obvious heterogeneity (I 2 =59.3%, P=0.008) was discovered by using a randomeffects model. Therefore, sensitivity analysis was performed to assess the stability of the results by successively omitting each study. Results showed the pooled HRs did not vary substantially by excluding any individual study, indicating a better stability of this meta-analysis ( Figure 3) . Furthermore, a meta-regression was conducted to investigate the potential responsible factors for the heterogeneity. It found that none of these factors, including region, cancer type, cases (as well as the number of patients with follow-up data), maximum follow-up month, tissue preservation, cutoff value, and analysis of variance was contributing to the heterogeneity significance.
Subgroup analyses were performed according to the following categories: cancer type, region, tissue preservation, and analysis of variance. As the results shown in Figure 4 OncoTargets and Therapy 2016:9 submit your manuscript | www.dovepress.com
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Xiao et al and (Table 3) . However, subgroups, such as osteosarcoma, NSCLC, formalin-fixed and paraffin-embedded (FFPE) tissue preservation, and univariate analysis, showed no statistically significant association between decreased miR-133a and OS outcome (Table 3 ).
Publication bias assessment
As shown in Figure 5 , we performed Begg's funnel plot and Egger's test to evaluate the publication bias for all articles in this meta-analysis. The P-values of Begg's and Egger's test were 0.37 and 0.15, respectively, suggesting no obvious risk of publication bias.
Discussion
In mammal cells, miR-133a performs many regulating functions. It regulates adipocyte browning in vivo 35 and modulates osteogenic differentiation of the vascular smooth muscle cells. 36 MiR-133a is also a biomarker for postmenopausal osteoporosis 37 and can predict cardiac hypertrophy in chronic hemodialysis patients. 38 In cancer research, miR-133a is regarded as a potential biomarker for breast cancer detection. 39 It inhibits the growth of cervical cancer and gastric cancer by targeting epidermal growth factor receptor and insulin-like growth factor-1 receptor, respectively. 40, 41 Therefore, miR-133a is considered to be a tumor suppressor. Consequently, downregulated miR-133a induces cancer progression and predicts poor prognosis in cancer patients. 24, 25 However, no meta-analyses are performed so far to evaluate the prognostic value of decreased miR-133a in patients with solid cancers. So, we have done this meta-analysis.
In our meta-analysis, ten eligible articles met the inclusion criteria. The outcome of cancer patients was collected by OS data. By using a random-effects model to get the pooled HRs, the combined results indicated that decreased miR-133a expression was associated with an unfavorable prognosis in patients with solid cancers. Sensitivity analysis showed that no individual study was obviously affecting the overall result, indicating the pooled result of this meta-analysis is stable. However, due to evident heterogeneity between the included studies, we conducted further subgroup analyses regarding cancer type, region, tissue preservation, and analysis of variance. Despite osteosarcoma, NSCLC, FFPE tissue preservation, and univariate analysis subgroups showed no statistically significant correlation between decreased miR133a and OS. While, compared with the total pooled HR, the subgroups of digestive system neoplasms, frozen tissue preservation, and multivariate analysis exhibited stronger connection between decreased miR-133a expression and OS outcome with relatively low heterogeneity. In addition, no publication bias was observed.
The results of this meta-analysis have several considerable implications. First, decreased miR-133a may be a common poor prognostic marker for solid cancers. The original researches of our meta-analysis were derived from five cancer types: osteosarcoma, 24, 28, 33 NSCLC, 26, 34 esophageal cancer, 31, 32 colorectal cancer, 25, 29 and pancreatic cancer. 27 As the pooled result from all these cancer types showed decreased non-small-cell lung cancer igF-1r, TgFBr1, and egFr Qin et al 27 
2013
Pancreatic cancer Fscn1
Abbreviations: anXa2, annexin a2; Bcl-xl, B-cell lymphoma-extra large; caV1, caveolin-1; egFr, epidermal growth factor receptor; Fscn1, Fascin-1; igF-1r, insulin-like growth factor 1 receptor; lasP1, liM and sh3 domain protein 1; MMP14, matrix metalloprotease 14; Mcl-1, myeloid cell leukemia-1; sgMs2, sphingomyelin synthase 2; SNX30, sorting nexin family member 30; TGFBR1, TGF-beta receptor type-1; UBA2, ubiquitin-like modifier activating enzyme 2.
miR-133a was correlated with a poor OS; thus, the conclusion can basically extend to all solid cancers. 42, 43 Second, decreased miR-133a probably is a reliable biomarker of poor survival for patients with digestive system neoplasms. Our analysis results showed that decreased miR-133a in patients with digestive system neoplasms exhibited poorer OS compared with osteosarcoma and NSCLC. However, the specific mechanism for this phenomenon needs to be explored in further research. Third, cancer tissues preserved by freezing may be more appropriate for microRNA detection than FFPE. Although studies showed consistent correlations between matched FFPE and frozen samples on the expression of microRNAs, 44, 45 the expression of a specific microRNA (eg, miR-133a) maybe is different. Unlike FFPF tissue preservation subgroup, our results indicated decreased miR-133a was obviously associated with poor prognosis in frozen tissues. It implicated that frozen tissues may reflect the expression of microRNA more actually than FFPE samples. Fourth, multivariate analysis maybe is more suitable for the researches on the correlation between microRNA expression and OS outcome in patients with cancer. The multivariate analysis subgroup in this meta-analysis exhibited stronger connection between decreased miR-133a expression and OS compared with the subgroup of univariate analysis. However, as the multivariate analysis ruled out the compounding effects from other factors, such as tumor size, stage, and nodal status, [24] [25] [26] the pooled results from studies conducted by multivariate analysis may be considered as more reliable.
In cancer, microRNAs act as tumor suppressors when they downregulate different proteins with oncogenic activity. 46 Similarly, microRNAs act as oncogenes if they downregulate genes involved in cell differentiation or as tumor suppressors. 46 For the ten original studies included in our meta-analysis, most of them reported that miR-133a functions as a tumor suppressor and the decreased expression of miR-133a was correlated with poor prognostic in patients with solid cancer while a few other studies reported inconsistent results, 28, 29, 34 indicating miR-133a maybe is a tumor promoter. We considered the reason for this paradox maybe is that miR-133a downregulated different target genes in different cancer types (Table 4) .
Except for miR-133a, the miR-133 family also contains miR-133b. Studies found that miR-133b acts as a tumor suppressor and its expression was decreased in many types of solid cancers, such as NSCLC, bladder cancer, ovarian cancer, and gastric cancer. [47] [48] [49] [50] In addition, many other
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Xiao et al studies also reported that both miR-133a and miR-133b were decreased together in solid cancer tissues. 31, [50] [51] [52] Further considering the results of our current meta-analysis, all these evidences indicate that the decreased expression of miR-133 family maybe is the reliable predictor, suggesting patients with solid cancer will have a poor prognosis.
Nevertheless, when interpreting the results of this metaanalysis, several limitations should be noticed. One of the main limitations is the limited region for the included source of cancer patients. Patient populations in this study were limited to Asia, lacking data from other regions, such as Europe, America, Oceania, and Africa. Our results need to be proved by more studies from other regions. Another limitation is that some HR data were extracted from survival curves, which may introduce bias. Thus, the present statistics seem to be less reliable than those directly obtained from published studies. If possible, pooled HRs should be performed based on directly obtained data from the published studies. In addition, all of the included studies in our meta-analysis were designed for retrospective studies, which are more possible to be published when they report positive rather than negative results. Consequently, the association between decreased miR-133a and poor OS may have been overestimated. Finally, obvious heterogeneity showed in between studies, even though we used random-effects models to calculate the pooled HRs. The heterogeneity may be attributed to the inconformity in different population characteristics, types of cancer, treatment strategies, and so on, which will likely reduce the reliability of this study and those findings similar to ours.
53,54
Conclusion
Our meta-analysis concluded that decreased miR-133a expression is significantly associated with poor OS in patients with solid cancer. However, our results also need to be cautiously considered because of the limitations described above. Further studies related to specific cancer types and large sample sizes are required to verify the prognostic value of decreased miR-133a in various cancers.
